Brickell Biotech Inc. (NASDAQ:BBI) does about 2.49M shares in volume on a normal day but saw 9484502 shares change hands in Friday trading. The company now has a market cap of 22.59M USD and an enterprise value of about $1.63M. Its current market price is $0.94, marking an increase of 15.55% compared to the previous close of $0.81. The 52 week high reached by this stock is $6.51 whilst the lowest price level in 52 weeks is $0.71. The script in recent trading has seen the stock touch a high of $0.97 and a low of $0.8149.

Brickell Biotech Inc. (BBI) has a 20-day trading average at $0.8654 and the current price is -85.53% off the 52-week high compared with 32.62% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.9284 and its 200-day simple moving average is $1.4045. If we look at the stock’s price movements over the week, volatility stands at 14.29%, which decreases to 6.87% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 56.44 to suggest the stock is neutral.

2 analysts observing the Brickell Biotech Inc. (BBI) stock have set the 12-month price targets for the company’s shares at between $5.00 and $6.00. The median price target is 82.91% away from the current levels at $5.50.

FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 28, 2020 when Lake Street initiated the stock to “Buy” and issued a price target of $6.

The current price level is 8.98%, 1.30%, and -33.24% away from its SMA20, SMA50, and SMA200 respectively, with the BBI price moving below the 50-day SMA on August 28. Brickell Biotech Inc. (BBI) stock is up 13.46% over the week and 0.19% over the past month. Its price is -37.22% year-to-date and -83.22% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2019, with the company’s earnings per share (EPS) of -$0.77 below consensus estimates by $0. The company’s next earnings report is expected on 11/11/2020. In addition, estimates put the company’s current quarterly revenue at an average of $1.18 million.

Its 12-month price target is $5.50. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $5.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $6.00.

Outstanding shares total 27.79M with insiders holding 14.31% of the shares and institutional holders owning 31.99% of the company’s common stock. The company has a return on investment of -291.40% and return on equity of -193.40%. The beta has a value of -0.19. Price to book ratio is 0.56 and price to sales ratio is 6.45.

According to a U.S. Securities and Exchange Commission filing, FCP Medical – BioHealth has added its position in Brickell Biotech Inc. (BBI) to 686,513 shares, mirroring a recent increase by 308.98%. FCP Medical – BioHealth added 0.52 million shares of Brickell Biotech Inc. common stock bringing its total worth to about $0.63 million at the end of recent close, SEC documents show. FCP Medical – BioHealth isn’t the only investment manager who changed stakes and is followed by Vanguard Total Stock Market Index, which sold off 0.0 shares to end up with 240,499 shares worth $0.22 million. Vanguard Extended Market Index Fu cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.38% position in Brickell Biotech Inc. thanks to 0.1 million shares amounting to $95549.0.